iRhythm Technologies, Inc. (NASDAQ:IRTC) Accelerates Revenue Growth Amid Data-Breach Risk

Stronger top-line momentum and improving operating leverage have narrowed losses and created short-term fundamental support; a recent cybersecurity disclosure, however, raises operational and reputational downside risk that could pressure sentiment and near-term price action.

Recent News

03/30/2026 — iRhythm presented three retrospective analyses at ACC.26 showing high diagnostic yield of Zio ambulatory ECG across cardiometabolic and kidney disease populations and launched the iRhythm Academy clinician education platform. 04/30/2026 — the company reported Q1 2026 results: revenue $199.39M, net loss $13.93M, adjusted EBITDA positive, and full-year 2026 revenue guidance of $875–$885M with adjusted EBITDA margin guidance of 12–13%. 06/17/2026 — iRhythm disclosed a cybersecurity incident discovered June 10 involving data exfiltration from third-party business applications and potential exposure of patient information affecting millions of records; company reports no evidence clinical device systems were compromised.

Technical Analysis

Directional indicators show a bearish bias despite low trend strength. ADX registers 11.89, indicating no dominant trend; DI+ peaked then reversed while DI- dipped then reversed, signaling recent strengthening of negative directional pressure that undermines near-term upside relative to the valuation baseline.

MACD sits negative at -2.61 with the MACD line below the signal (-2.30) and a peak-and-reversal pattern, indicating declining momentum and reinforcing the probability of continued near-term weakness versus the current valuation.

MRO reads 0.98 and has peaked then reversed; the positive MRO implies price sits modestly above WMDST’s regression target and therefore carries mild downside potential back toward that target in the coming weeks.

RSI at 42.14 with a peak-and-reversal pattern signals faded bullish momentum and room for further pullback before oversold thresholds, aligning with MACD and MRO indications of weakening internals.

Price structure favors resistance. Last close $104.69 trades below the 20-day average $108.61, the 50-day average $116.05, and the 200-day average $150.14; the Tenkan-Sen $109.47 and Kijun-Sen $112.00 sit above price and the Ichimoku cloud (Senkou A $121.69 / Senkou B $138.50) places cloud resistance well overhead, all of which establish a multi-timeframe cap on near-term recovery attempts.

Volatility and volume context: 20-day SD $4.72 and muted 42-/52-week volatilities (~0.03) support a low to moderate realized volatility regime, while recent volume (298,856) falls below 10/50/200-day averages, suggesting any directional move lacks broad participation at present.

 


Fundamental Analysis

Top line and margins: total revenue for the quarter reached $199.39M and YoY revenue growth registers 32.33%, while quarter-over-quarter revenue shows a contraction of 154.81% as reported. Gross margin stands at 70.89%, improving 2.999 percentage points YoY, which supports operating leverage but has not yet translated to positive operating margins.

Profitability and cash flow: net loss for the quarter totaled $13.93M, operating margin equals -8.12% and EBIT margin equals -5.49%; EBIT and EBITDA remain negative at -$10.95M and -$4.41M respectively. Free cash flow was negative $33.08M for the period, though cash and short-term investments total $549.62M and unrestricted liquidity provides runway against near-term obligations.

Balance sheet and leverage: current ratio of 5.17 and quick ratio of 4.98 indicate strong short-term liquidity, while debt-to-assets at 72.47% and debt-to-equity of 452.39% reflect elevated leverage driven by convertible notes and long-term debt.

Earnings and estimates: reported EPS was -$0.35 versus an estimate of -$0.64, producing an EPS surprise of +45.31%, and forward EPS consensus implies a steeply elevated forward P/E of ~537.6x as reported. Price-to-book at 26.71x sits above the industry peer mean (5.62x), median (4.17x), and the industry peer range high (20.94x), underscoring valuation dispersion relative to peers. WMDST values the stock as over-valued; enterprise-to-revenue (EVR) registers ~22.50x and price-to-sales sits at 21.60x, metrics that align with that assessment given current earnings and cash-flow dynamics.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-04-30
NEXT REPORT DATE: 2026-07-30
CASH FLOW  Begin Period Cash Flow 244.4 M
 Operating Cash Flow -26.17 M
 Capital Expenditures -6.91 M
 Change In Working Capital -67.39 M
 Dividends Paid
 Cash Flow Delta 4.1 M
 End Period Cash Flow 248.5 M
 
INCOME STATEMENT REVENUE
 Total Revenue 199.4 M
 Forward Revenue -30.89 M
COSTS
 Cost Of Revenue 58.0 M
 Depreciation 6.5 M
 Depreciation and Amortization 6.5 M
 Research and Development 21.7 M
 Total Operating Expenses 215.6 M
PROFITABILITY
 Gross Profit 141.4 M
 EBITDA -4.41 M
 EBIT -10.95 M
 Operating Income -16.18 M
 Interest Income 4.9 M
 Interest Expense 2.5 M
 Net Interest Income 1.6 M
 Income Before Tax -13.43 M
 Tax Provision 500.0 K
 Tax Rate 40.0 %
 Net Income -13.93 M
 Net Income From Continuing Operations -13.93 M
EARNINGS
 EPS Estimate -0.64
 EPS Actual -0.35
 EPS Difference 0.29
 EPS Surprise 45.313 %
 Forward EPS 0.26
 
BALANCE SHEET ASSETS
 Total Assets 1.0 B
 Intangible Assets 862.0 K
 Net Tangible Assets 160.3 M
 Total Current Assets 680.6 M
 Cash and Short-Term Investments 549.6 M
 Cash 240.1 M
 Net Receivables 80.9 M
 Inventory 23.8 M
 Long-Term Investments 55.1 M
LIABILITIES
 Accounts Payable 8.6 M
 Short-Term Debt
 Total Current Liabilities 131.8 M
 Net Debt 410.2 M
 Total Debt 729.3 M
 Total Liabilities 845.2 M
EQUITY
 Total Equity 161.2 M
 Retained Earnings -817.38 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 4.91
 Shares Outstanding 32.854 M
 Revenue Per-Share 6.07
VALUATION
 Market Capitalization 4.3 B
 Enterprise Value 4.5 B
 Enterprise Multiple -1017.592
Enterprise Multiple QoQ -443.159 %
Enterprise Multiple YoY 510.239 %
Enterprise Multiple IPRWA high: 167.868
mean: 82.388
median: 80.811
low: -193.913
IRTC: -1017.592
 EV/R 22.496
CAPITAL STRUCTURE
 Asset To Equity 6.243
 Asset To Liability 1.191
 Debt To Capital 0.819
 Debt To Assets 0.725
Debt To Assets QoQ 1.097 %
Debt To Assets YoY -8.752 %
Debt To Assets IPRWA IRTC: 0.725
high: 0.681
mean: 0.266
median: 0.249
low: 0.002
 Debt To Equity 4.524
Debt To Equity QoQ -5.496 %
Debt To Equity YoY -46.695 %
Debt To Equity IPRWA IRTC: 4.524
high: 3.375
mean: 0.514
median: 0.426
low: -0.465
PRICE-BASED VALUATION
 Price To Book (P/B) 26.71
Price To Book QoQ -23.086 %
Price To Book YoY -29.403 %
Price To Book IPRWA IRTC: 26.71
high: 20.943
mean: 5.622
median: 4.172
low: -12.173
 Price To Earnings (P/E) -374.46
Price To Earnings QoQ -138.76 %
Price To Earnings YoY 246.255 %
Price To Earnings IPRWA high: 194.313
mean: 120.3
median: 98.047
low: -198.766
IRTC: -374.46
 PE/G Ratio 1.224
 Price To Sales (P/S) 21.595
Price To Sales QoQ -14.957 %
Price To Sales YoY 4.507 %
Price To Sales IPRWA high: 62.134
mean: 29.551
median: 21.968
IRTC: 21.595
low: 0.285
FORWARD MULTIPLES
Forward P/E 537.577
Forward PE/G -1.757
Forward P/S -140.451
EFFICIENCY OPERATIONAL
 Operating Leverage 42.647
ASSET & SALES
 Asset Turnover Ratio 0.197
Asset Turnover Ratio QoQ -5.075 %
Asset Turnover Ratio YoY 15.183 %
Asset Turnover Ratio IPRWA high: 0.411
IRTC: 0.197
median: 0.128
mean: 0.121
low: 0.002
 Receivables Turnover 2.547
Receivables Turnover Ratio QoQ -7.417 %
Receivables Turnover Ratio YoY 28.877 %
Receivables Turnover Ratio IPRWA high: 3.141
IRTC: 2.547
mean: 1.934
median: 1.582
low: 0.361
 Inventory Turnover 2.555
Inventory Turnover Ratio QoQ -13.505 %
Inventory Turnover Ratio YoY -26.718 %
Inventory Turnover Ratio IPRWA IRTC: 2.555
high: 1.854
mean: 0.604
median: 0.509
low: 0.137
 Days Sales Outstanding (DSO) 35.827
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 61.79
Cash Conversion Cycle Days QoQ 6.069 %
Cash Conversion Cycle Days YoY 12.959 %
Cash Conversion Cycle Days IPRWA high: 587.726
median: 180.7
mean: 160.977
IRTC: 61.79
low: -133.614
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.363
 CapEx To Revenue -0.035
 CapEx To Depreciation -1.055
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 811.5 M
 Net Invested Capital 811.5 M
 Invested Capital 811.5 M
 Net Tangible Assets 160.3 M
 Net Working Capital 548.8 M
LIQUIDITY
 Cash Ratio 4.172
 Current Ratio 5.166
Current Ratio QoQ 11.644 %
Current Ratio YoY -9.569 %
Current Ratio IPRWA high: 14.36
IRTC: 5.166
mean: 2.715
median: 2.112
low: 0.038
 Quick Ratio 4.985
Quick Ratio QoQ 11.161 %
Quick Ratio YoY -10.719 %
Quick Ratio IPRWA high: 12.588
IRTC: 4.985
mean: 1.999
median: 1.518
low: 0.37
COVERAGE & LEVERAGE
 Debt To EBITDA -165.447
 Cost Of Debt 0.204 %
 Interest Coverage Ratio -4.417
Interest Coverage Ratio QoQ -313.363 %
Interest Coverage Ratio YoY -60.25 %
Interest Coverage Ratio IPRWA high: 87.935
mean: 18.052
median: 13.911
IRTC: -4.417
low: -102.892
 Operating Cash Flow Ratio -0.064
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 8.111
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate -1.341 %
 Revenue Growth -4.548 %
Revenue Growth QoQ -154.808 %
Revenue Growth YoY 32.325 %
Revenue Growth IPRWA high: 16.503 %
IRTC: -4.548 %
median: -6.009 %
mean: -7.849 %
low: -65.483 %
 Earnings Growth -305.882 %
Earnings Growth QoQ -20.205 %
Earnings Growth YoY -96.814 %
Earnings Growth IPRWA high: 200.0 %
median: -7.623 %
mean: -14.282 %
low: -145.833 %
IRTC: -305.882 %
MARGINS
 Gross Margin 70.893 %
Gross Margin QoQ 0.023 %
Gross Margin YoY 2.999 %
Gross Margin IPRWA high: 95.029 %
IRTC: 70.893 %
mean: 63.477 %
median: 63.289 %
low: 7.731 %
 EBIT Margin -5.493 %
EBIT Margin QoQ -198.423 %
EBIT Margin YoY -68.367 %
EBIT Margin IPRWA high: 63.148 %
median: 21.811 %
mean: 20.484 %
IRTC: -5.493 %
low: -233.035 %
 Return On Sales (ROS) -8.117 %
Return On Sales QoQ -438.773 %
Return On Sales YoY -53.257 %
Return On Sales IPRWA high: 63.148 %
mean: 20.623 %
median: 20.603 %
IRTC: -8.117 %
low: -219.267 %
CASH FLOW
 Free Cash Flow (FCF) -33.08 M
 Free Cash Flow Yield -0.768 %
Free Cash Flow Yield QoQ -381.319 %
Free Cash Flow Yield YoY 45.455 %
Free Cash Flow Yield IPRWA high: 7.748 %
mean: 0.523 %
median: 0.47 %
IRTC: -0.768 %
low: -15.26 %
 Free Cash Growth -328.297 %
Free Cash Growth QoQ 1083.351 %
Free Cash Growth YoY 36.943 %
Free Cash Growth IPRWA high: 324.237 %
mean: -30.579 %
median: -37.858 %
IRTC: -328.297 %
low: -397.308 %
 Free Cash To Net Income 2.374
 Cash Flow Margin -4.217 %
 Cash Flow To Earnings 0.603
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) -1.375 %
Return On Assets QoQ -348.195 %
Return On Assets YoY -58.396 %
Return On Assets IPRWA high: 5.251 %
mean: 2.066 %
median: 1.583 %
IRTC: -1.375 %
low: -28.223 %
 Return On Capital Employed (ROCE) -1.252 %
 Return On Equity (ROE) -0.086
Return On Equity QoQ -336.665 %
Return On Equity YoY -75.601 %
Return On Equity IPRWA high: 0.413
median: 0.032
mean: 0.031
IRTC: -0.086
low: -0.899
 DuPont ROE -8.876 %
 Return On Invested Capital (ROIC) -0.81 %
Return On Invested Capital QoQ -160.223 %
Return On Invested Capital YoY -64.048 %
Return On Invested Capital IPRWA high: 8.753 %
mean: 2.464 %
median: 2.32 %
IRTC: -0.81 %
low: -14.938 %

Six-Week Outlook

Expect range-bound to modestly lower price action absent a clear relief on the cybersecurity disclosure; technical internals (negative MACD, price below key moving averages, DI+/DI- reversal) favor downside pressure toward near-term support near the lower Bollinger band (~$103.89) and the 52-week low ($100.85). Positive fundamental catalysts that could shift the outlook include execution against the revenue guidance and clear resolution or containment of the data-exfiltration incident; conversely, widening scope or regulatory scrutiny around the breach would heighten downside risk relative to the current over-valued baseline. Monitor volume-normalized breakouts or MACD recovery above the signal line for any durable shift in momentum, and reassess as company disclosures or material developments arrive.

About iRhythm Technologies, Inc.

iRhythm Technologies, Inc. (NASDAQ:IRTC) develops advanced cardiac monitoring solutions, transforming arrhythmia diagnosis and management. Based in San Francisco, California, iRhythm delivers innovative healthcare technology through its Zio services, which include long-term and short-term continuous monitoring and mobile cardiac telemetry. These services enable precise detection of heart rhythm disorders, offering healthcare providers comprehensive tools for accurate diagnosis. The Zio Monitor System, a key component of iRhythm’s offerings, provides a prescription-only, remote electrocardiogram (ECG) monitoring solution. This system utilizes a discreet patch that records heart signals for up to 14 days, allowing for detailed data collection. The Zio XT and Zio AT systems enhance patient care by offering continuous ECG monitoring, with the Zio AT incorporating wireless connectivity for seamless data transmission. iRhythm collaborates with Verily Life Sciences and Verity Ireland Limited to advance technologies for atrial fibrillation screening and detection. Since its founding in 2006, iRhythm has committed to delivering patient-centric solutions that empower healthcare providers to make informed decisions, ultimately improving outcomes in cardiac health.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.